Evidence map›Paper›PMID 40178707›Full record

ReviewGeroScience2025

NIA Caenorhabditis Intervention Testing Program: identification of robust and reproducible pharmacological interventions that promote longevity across experimentally accessible, genetically diverse populations.

Monica Driscoll, Christine A Sedore, Brian Onken, Anna L Coleman-Hulbert, Erik Johnson, Patrick C Phillips, Gordon Lithgow

Abstract readReview
In one paragraph

Review in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. High-Throughput Toxicity Screening withEnvironmental science & technology · 2026
    Review
  6. microPublication biology · 2026
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Monica DriscollRutgers, The State University of New Jersey, Piscataway, NJ, USA. driscoll@dls.rutgers.edu.ORCID 0000-0002-8751-7429
Christine A SedoreUniversity of Oregon, Eugene, USA.
Brian OnkenRutgers, The State University of New Jersey, Piscataway, NJ, USA.
Anna L Coleman-HulbertUniversity of Oregon, Eugene, USA.
Erik JohnsonUniversity of Oregon, Eugene, USA.
Patrick C PhillipsUniversity of Oregon, Eugene, USA.
Gordon LithgowBuck Institute for Research on Aging, Novato, CA, USA.

Funding

Discovering compounds with robust pro-longevity activitiesU01AG045844 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI Gordon J Lithgow · 2013 to 2026
$10.1M
Healthspan Analysis of C. elegans Strains Treated with Candidate Anti Aging InterU01AG045864 · NIA · RUTGERS, THE STATE UNIV OF N.J. · PI MONICA A. DRISCOLL · 2013 to 2026
$8.1M
Genetic variation underlying the response to longevity interventionsU01AG045829 · NIA · UNIVERSITY OF OREGON · PI Patrick C. Phillips · 2013 to 2026
$8.0M
Caenorhabditis Testing Program Data Coordinating CenterU24AG056052 · NIA · UNIVERSITY OF OREGON · PI Patrick C. Phillips · 2017 to 2026
$2.2M
NIA NIH HHS U01 AG045829NIA NIH HHS U01 AG045844NIA NIH HHS U01 AG045864NIA NIH HHS U24 AG056052
6 · The paper itself

Abstract

A core facet of the National Institute on Aging's mission is to identify pharmacological interventions that can promote human healthy aging and long life. As part of the comprehensive effort toward that goal, the NIA Division of Biology of Aging established the Caenorhabditis Intervention Testing Program (CITP) in 2013. The C. elegans model (with an ~ 21 day lifespan) has led the field in dissection of longevity genetics and offers features that allow for relatively rapid testing and for the potential elaboration of biological mechanisms engaged by candidate geroprotectants. CITP builds on this foundation by utilizing a genetically diverse set of intervention test strains so that "subjects" represent genetic diversity akin to that that between mouse and humans. Another distinctive aspect of the CITP is a dedicated focus on reproducibility of longevity outcomes as labs at three independent test sites confirm positive outcomes. The overall goal of the Caenorhabditis Intervention Testing Program (CITP) is to identify robust and reproducible pro-longevity interventions affecting genetically diverse cohorts in the Caenorhabditis genus. A strong Data Collection Center supports data collection and dissemination. Pharmacological interventions tested by CITP can be nominated by the general public, directed by in-house screens, or supported by published scientific literature. As of December 2024, CITP tested > 75 compounds and conducted > 725,000 animal assays over 891 trials. We identified 12 compounds that confer a ≥ 20% increase in median lifespan to reproducibly and robustly extend lifespan across multiple strains and labs. Five of these interventions have pro-longevity impact reported in the mouse literature (most CITP positive interventions are not tested yet in mouse). As part of the celebration of the 50th Anniversary of the NIA, we review the development history and accomplishments of the CITP program, and we comment on translation and the promise of advancing understanding of fundamental aging biology that includes the pharmacological intervention/health interface.

Indexed as

Caenorhabditis elegansLongevityAnimalsGenetic VariationHumansMiceModels, AnimalNational Institute on Aging (U.S.)Reproducibility of ResultsUnited StatesC. elegansGenetic diversityGenetic modelHealthy agingPharmacological interventionsPro-longevityReproducibility

Identifiers

PMID40178707
PMCPMC12181528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.